BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

2:31 PM
 | 
Sep 29, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

China approves HCV drugs from Gilead and AbbVie

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir (GS-7977) to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older.

Gilead said the nucleotide analog HCV NS5B polymerase inhibitor is the first HCV drug from the company to receive Chinese approval....

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >